Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy

Valerie M. Nelson, Al B Benson III*

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Both the addition of neoadjuvant chemoradiation therapy and improvements in surgical techniques have improved local control and overall survival for locally advanced rectal cancer patients over the past few decades. The addition of adjuvant chemotherapy has likely improved outcomes as well, though the contribution has been more difficult to quantify. At present, the majority of resected locally advanced rectal cancer patients receive adjuvant chemotherapy, though there is great variability in this practice based on both patient and institution characteristics. Recently, questions have been raised regarding which sub-groups of patients benefit most from adjuvant chemotherapy. As pathologic complete response (pCR) is increasingly found to be a reasonable surrogate for long-term favorable outcomes, some have questioned the need for adjuvant therapy in this select group of patients. Multiple retrospective analyses have shown minimal to no benefit for adjuvant chemotherapy in this group. Indeed, the patients most consistently shown to benefit from adjuvant therapy both in terms of disease free survival (DFS) and overall survival (OS) are those who achieve an intermediate pathologic response to neoadjuvant treatment. Tumors that have high expression of thymidylate synthetase have also shown to benefit from adjuvant therapy. More study is needed into clinical and molecular features that predict patient benefit from adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)152-161
Number of pages10
JournalCurrent oncology reports
Volume15
Issue number2
DOIs
StatePublished - Apr 1 2013

Fingerprint

Neoadjuvant Therapy
Rectal Neoplasms
Adjuvant Chemotherapy
Therapeutics
Thymidylate Synthase
Survival
Disease-Free Survival

Keywords

  • Adjuvant therapy
  • Neoadjuvant therapy
  • Pathologic response
  • Rectal cancer

ASJC Scopus subject areas

  • Oncology

Cite this

@article{45707c0b49f6432eb71e848564fc0db8,
title = "Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy",
abstract = "Both the addition of neoadjuvant chemoradiation therapy and improvements in surgical techniques have improved local control and overall survival for locally advanced rectal cancer patients over the past few decades. The addition of adjuvant chemotherapy has likely improved outcomes as well, though the contribution has been more difficult to quantify. At present, the majority of resected locally advanced rectal cancer patients receive adjuvant chemotherapy, though there is great variability in this practice based on both patient and institution characteristics. Recently, questions have been raised regarding which sub-groups of patients benefit most from adjuvant chemotherapy. As pathologic complete response (pCR) is increasingly found to be a reasonable surrogate for long-term favorable outcomes, some have questioned the need for adjuvant therapy in this select group of patients. Multiple retrospective analyses have shown minimal to no benefit for adjuvant chemotherapy in this group. Indeed, the patients most consistently shown to benefit from adjuvant therapy both in terms of disease free survival (DFS) and overall survival (OS) are those who achieve an intermediate pathologic response to neoadjuvant treatment. Tumors that have high expression of thymidylate synthetase have also shown to benefit from adjuvant therapy. More study is needed into clinical and molecular features that predict patient benefit from adjuvant therapy.",
keywords = "Adjuvant therapy, Neoadjuvant therapy, Pathologic response, Rectal cancer",
author = "Nelson, {Valerie M.} and {Benson III}, {Al B}",
year = "2013",
month = "4",
day = "1",
doi = "10.1007/s11912-013-0297-5",
language = "English (US)",
volume = "15",
pages = "152--161",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "2",

}

Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy. / Nelson, Valerie M.; Benson III, Al B.

In: Current oncology reports, Vol. 15, No. 2, 01.04.2013, p. 152-161.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy

AU - Nelson, Valerie M.

AU - Benson III, Al B

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Both the addition of neoadjuvant chemoradiation therapy and improvements in surgical techniques have improved local control and overall survival for locally advanced rectal cancer patients over the past few decades. The addition of adjuvant chemotherapy has likely improved outcomes as well, though the contribution has been more difficult to quantify. At present, the majority of resected locally advanced rectal cancer patients receive adjuvant chemotherapy, though there is great variability in this practice based on both patient and institution characteristics. Recently, questions have been raised regarding which sub-groups of patients benefit most from adjuvant chemotherapy. As pathologic complete response (pCR) is increasingly found to be a reasonable surrogate for long-term favorable outcomes, some have questioned the need for adjuvant therapy in this select group of patients. Multiple retrospective analyses have shown minimal to no benefit for adjuvant chemotherapy in this group. Indeed, the patients most consistently shown to benefit from adjuvant therapy both in terms of disease free survival (DFS) and overall survival (OS) are those who achieve an intermediate pathologic response to neoadjuvant treatment. Tumors that have high expression of thymidylate synthetase have also shown to benefit from adjuvant therapy. More study is needed into clinical and molecular features that predict patient benefit from adjuvant therapy.

AB - Both the addition of neoadjuvant chemoradiation therapy and improvements in surgical techniques have improved local control and overall survival for locally advanced rectal cancer patients over the past few decades. The addition of adjuvant chemotherapy has likely improved outcomes as well, though the contribution has been more difficult to quantify. At present, the majority of resected locally advanced rectal cancer patients receive adjuvant chemotherapy, though there is great variability in this practice based on both patient and institution characteristics. Recently, questions have been raised regarding which sub-groups of patients benefit most from adjuvant chemotherapy. As pathologic complete response (pCR) is increasingly found to be a reasonable surrogate for long-term favorable outcomes, some have questioned the need for adjuvant therapy in this select group of patients. Multiple retrospective analyses have shown minimal to no benefit for adjuvant chemotherapy in this group. Indeed, the patients most consistently shown to benefit from adjuvant therapy both in terms of disease free survival (DFS) and overall survival (OS) are those who achieve an intermediate pathologic response to neoadjuvant treatment. Tumors that have high expression of thymidylate synthetase have also shown to benefit from adjuvant therapy. More study is needed into clinical and molecular features that predict patient benefit from adjuvant therapy.

KW - Adjuvant therapy

KW - Neoadjuvant therapy

KW - Pathologic response

KW - Rectal cancer

UR - http://www.scopus.com/inward/record.url?scp=84879606021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879606021&partnerID=8YFLogxK

U2 - 10.1007/s11912-013-0297-5

DO - 10.1007/s11912-013-0297-5

M3 - Article

C2 - 23381584

AN - SCOPUS:84879606021

VL - 15

SP - 152

EP - 161

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 2

ER -